Phase 1/2 Open Label, Dose-escalation Study of the Safety and OcUlar Tolerability of a Single Intravitreal Injection of RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration (SUSHI)
Phase of Trial: Phase I/II
Latest Information Update: 30 Oct 2018
At a glance
- Drugs RBM 007 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms SUSHI
- Sponsors Ribomic
- 30 Oct 2018 According to a Ribomic media release, first patient has been enrolled.
- 20 Sep 2018 Status changed from not yet recruiting to recruiting.
- 23 Aug 2018 New trial record